AzTrials
AzTrials

PneumoperitoneumVeress+NCT05613959

Evaluating the Novel Veress Plus Needle

An observational study of Pneumoperitoneum, run by Prof Jean Calleja-Agius at 1 site in Malta.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

18 participants (novices, intermediates and experts) performed in total 248 insertions in a systematic way on Thiel embalmed bodies with wide and small bore versions of the conventional VNc (conventional Veress Needle) and the VN+(The Veress Needle plus). Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Pneumoperitoneum
What is being tested?
Veress + and Conventional Veress
Type of treatment
Medical device
How many people
18 participants
Where
1 siteMalta
Study dates
1 Jan 2021to 26 Sep 2021
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Surgical residents, young surgeons, exeprienced surgeons from the University of Malta Mater Dei Hospital

Who may be able to join

  • medical background, healthy

Who cannot join

  • physically or mentally handicapped

Trial locations and contacts

1 site in 1 country.

Malta1 site
  • Laboratory for Anatomy

    Valletta, MSD 2080

Other trials in Malta

About this study

Official title: Evaluation of the New Veress Needle+ Mechanism; A Study on Thiel-embalmed Bodies.

18 participants (novices, intermediates and experts) performed in total 248 insertions in a systematic way on Thiel embalmed bodies with wide and small bore versions of the conventional VNc (conventional Veress Needle) and the VN+(The Veress Needle plus). Insertion depth was measured by recording the graduations on the needle under direct laparoscopic vision.

Read the detailed description

In total two Thiel embalmed bodies were used over three days. The first body was a 72 year old male with no previous laparotomy or abdominal scars, who had died of myocardial infarction (Length: 170 cm; bodyweight: 70 kg). The 2nd body was a male of 65 years without abdominal scars. The cause of death had been a hospital acquired pneumonia and pulmonary embolism secondary to metastatic pancreatic cancer (length186 cm; bodyweight: 80kg).

An Aesculap laparoscopy tower set up (Aesculap, 3773 Corporate Parkway, Center Valley, 18034 PA, USA) was used with a 10 mm 30 degrees scope, which was inserted through a balloon trocar (Medtronic Netherlands, Larixplein 4, 5616VB Eindhoven, The Netherlands) in the abdomen just below the umbilicus. Intra-abdominal pressure was stabilized using CO2 (Carbon Dioxide) to 4 mm Hg(Mercury). This pressure-level was as low as possible to allow for unambiguous visualization of the insertions but almost equalling normal abdominal pressure. Two different needle types were used, a thin bore needle with a diameter of 2 millimeter (mm) and a length of 145 mm and a wide bore with 2.8 mm diameter and 145 mm length. The study was registered under number FRECMDS-2021-134 of the Ethical Committee of Faculty of Medicine and Surgery of the University of Malta.

Questionnaire The investigators used a questionnaire which consisted of questions about gender, age and previous experience. A 1 to 5 Likert scale was used to score the "life-likeness" of the Thiel embalmed bodies, realism of the procedure, safety the VN+ procedure, and difficulty of using the new needle design.

Protocol After completing the first part of the questionnaire, the participants were instructed and explained how the mechanism works. During the instruction phase, they were allowed to try the needle on a dedicated area, away from the intended research area, until they were able to manage their grip and found their best insertion strategies. To minimize the risk of hitting organs upon entering the abdominal cavity, certain areas are dedicated for VN (Veress Needle) placement such as Palmer's point in the left upper quadrant of the abdomen. In order to use the bodies as efficiently as possible whilst offering a similar experience in terms of abdominal composition to all participants, the whole upper part of the abdomen was used for the insertions, which were done in an alternating fashion (with and without the safety mechanism) for 12 punctures (2x6) from cranial to caudal so a "fresh" part (with no defect or lesion) of abdominal wall was used for each attempt. The participants were with their backs to the video monitor so they were blinded to what was happening inside the abdomen. Insertion of the VN+ was successful when the mechanism fully unlocked. If not, the attempt was noted as an unsuccessful trial, the cause was determined and the insertion data was removed. After the hands- on part, the participants were asked to fill out the last part of the questionnaire with questions about the quality of the bodies and procedures based on their personal experiences and the difficulty of using the VN+ device. It is important to note that the VN+ dislodge action is not influenced by the amount of insertion force but only by the position of the inner stylet.

Data comparison and Statistical analysis Video footage was used by three observers to determine the insertion depth, indicated by the number of markings engraved on the part of the needle surface inside the abdomen. The true insertion depth was calculated in Excel based on the known distance between each marking. After the participants completed the tests, any differences in maximum insertion depth between the VNc and VN+ groups were determined with a Student's t-test (SPSS v16, SPSS, Inc., Chicago, IL). A p-value < 0.05 was considered a significant difference. The same was done comparing the wide bore with the small bore needles and other variables including the different genders. The potential learning curve was established based on a regression analysis executed on the averaged outcomes per trial including all trial data. The potential influence of wear was established based on a regression analysis conducted on 12 separately executed trials with the wide bore needles. Wear is defined as diminishing sharpness of the bevel of the Veress needle after each attempt. For the regression analysis a p-value <0.05 was considered significantly different.

Being tested
Veress +, Conventional Veress
Keywords
Veress Needle, Thiel Embalmed Cadavers, Laparoscopy, Safety mechanism
Medical subject headings
Pneumoperitoneum

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Veress +Device

    The Veress+ safety mechanism was used

  • Conventional VeressDevice

    The Conventional Veress Needle was used

Study groups in NCT05613959
Study groupRoleWhat they receive
Veress +The Veress+ system was used
Receives: Device: Veress +
Veress conventionalThe Conventional Veress needle was used
Receives: Device: Conventional Veress

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. depth of insertion

    the depth of insertion of the needle into the abdominal cavity

    Measured: 20 minutes

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Nov 2022
  2. Study start1 Jan 2021
  3. Primary completion26 Sep 2021
  4. Study completion26 Sep 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
18 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05613959
Sponsor's protocol ID
UM 0001
Acronym
Veress+
Status last verified
Nov 2022
First submitted
17 Oct 2022
Last updated
14 Nov 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Pneumoperitoneum, run by Prof Jean Calleja-Agius at 1 site in Malta.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 14 Nov 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Malta. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

depth of insertion (time frame: 20 minutes). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Nov 2022.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in